Imperva Inc (IMPV) Expected to Announce Quarterly Sales of $82.29 Million
Brokerages predict that Imperva Inc (NYSE:IMPV) will post $82.29 million in sales for the current fiscal quarter, Zacks reports. Seven analysts have made estimates for Imperva’s earnings. The lowest sales estimate is $82.01 million and the highest is $82.98 million. Imperva posted sales of $68.41 million in the same quarter last year, which suggests a positive year over year growth rate of 20.3%. The firm is scheduled to issue its next quarterly earnings results on Thursday, November 2nd.
On average, analysts expect that Imperva will report full-year sales of $82.29 million for the current year, with estimates ranging from $320.90 million to $322.76 million. For the next year, analysts anticipate that the company will report sales of $379.23 million per share, with estimates ranging from $369.00 million to $386.30 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Imperva.
Imperva (NYSE:IMPV) last released its earnings results on Thursday, July 27th. The software maker reported ($0.10) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of $0.05 by $0.15. Imperva had a negative return on equity of 5.00% and a negative net margin of 4.69%. The firm had revenue of $74.44 million during the quarter, compared to analyst estimates of $74.30 million. During the same quarter last year, the business posted ($0.23) EPS. The firm’s revenue was up 28.6% on a year-over-year basis.
Several equities research analysts recently commented on the company. UBS AG assumed coverage on Imperva in a research note on Tuesday, June 6th. They issued a “positive” rating and a $60.00 price target for the company. BidaskClub cut Imperva from a “hold” rating to a “sell” rating in a research note on Saturday, August 5th. Zacks Investment Research raised Imperva from a “hold” rating to a “strong-buy” rating and set a $52.00 price target for the company in a research note on Wednesday, August 2nd. Stifel Nicolaus reissued a “hold” rating and issued a $47.00 price target on shares of Imperva in a research note on Friday, July 14th. Finally, Monness Crespi & Hardt upped their target price on Imperva from $55.00 to $57.00 and gave the stock a “buy” rating in a research report on Friday, July 28th. Two analysts have rated the stock with a sell rating, seven have given a hold rating, twelve have assigned a buy rating and one has given a strong buy rating to the stock. Imperva presently has an average rating of “Buy” and an average target price of $51.25.
WARNING: This report was first posted by Daily Political and is owned by of Daily Political. If you are reading this report on another website, it was copied illegally and reposted in violation of US & international copyright and trademark law. The original version of this report can be accessed at https://www.dailypolitical.com/2017/08/10/imperva-inc-impv-expected-to-announce-quarterly-sales-of-82-29-million.html.
Shares of Imperva (NYSE:IMPV) opened at 44.20 on Thursday. Imperva has a 1-year low of $34.40 and a 1-year high of $57.24. The firm’s market cap is $1.49 billion. The stock has a 50 day moving average of $47.95 and a 200 day moving average of $45.31.
In other news, SVP Sunil D. Nagdev sold 4,857 shares of the firm’s stock in a transaction on Tuesday, May 16th. The stock was sold at an average price of $49.00, for a total value of $237,993.00. Following the completion of the sale, the senior vice president now directly owns 16,290 shares in the company, valued at $798,210. The sale was disclosed in a filing with the SEC, which is accessible through this link. Also, insider Amichai Shulman sold 3,089 shares of the firm’s stock in a transaction on Monday, May 15th. The shares were sold at an average price of $48.70, for a total value of $150,434.30. Following the completion of the sale, the insider now owns 100,151 shares of the company’s stock, valued at $4,877,353.70. The disclosure for this sale can be found here. Corporate insiders own 2.20% of the company’s stock.
Several hedge funds have recently made changes to their positions in IMPV. North Run Capital LP boosted its position in Imperva by 999.3% in the first quarter. North Run Capital LP now owns 750,000 shares of the software maker’s stock valued at $30,788,000 after buying an additional 681,772 shares in the last quarter. Clearbridge Investments LLC boosted its position in Imperva by 47.0% in the first quarter. Clearbridge Investments LLC now owns 1,262,507 shares of the software maker’s stock valued at $51,826,000 after buying an additional 403,809 shares in the last quarter. BNP Paribas Arbitrage SA boosted its position in Imperva by 8,392.3% in the first quarter. BNP Paribas Arbitrage SA now owns 200,927 shares of the software maker’s stock valued at $8,248,000 after buying an additional 198,561 shares in the last quarter. Eagle Asset Management Inc. boosted its position in Imperva by 17.7% in the second quarter. Eagle Asset Management Inc. now owns 1,279,848 shares of the software maker’s stock valued at $61,240,000 after buying an additional 192,625 shares in the last quarter. Finally, Caisse DE Depot ET Placement DU Quebec purchased a new position in Imperva during the first quarter valued at about $7,192,000. Institutional investors own 92.72% of the company’s stock.
Imperva, Inc provides cyber-security solutions that protect business-critical data and applications whether in the cloud or on premises. The Company is engaged in the development, marketing, sales, service and support of cyber-security solutions. The Company’s products include its Imperva SecureSphere Paltform, Imperva CounterBreach and Imperva Camouflage for enterprise data centers, and Imperva Incapsula offering for cloud-based security services.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Imperva Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Imperva Inc and related companies with MarketBeat.com's FREE daily email newsletter.